| abstract |
The present invention is directed to therapeutic methods that use IL-6 antagonists, such as an antibody or antibody fragment Ab1 that has specificity of binding to IL-6 to prevent or treat the disease or improve the ability to survive or the quality of life of a patient who needs it. In preferred embodiments, these patients will comprise those who present (or are at risk of developing) a high serum C-reactive protein level, a reduced serum albumin level, D-dimer or other cascade-related protein or proteins high coagulation, cachexia, fever, weakness and / or fatigue before treatment. The therapies object of the present may also include the administration of other assets such as chemotherapeutic agents, anticoagulants, statins and others. |